Results 211 to 220 of about 602,989 (338)
HCN2‐Associated Neurodevelopmental Disorders: Data from Patients and Xenopus Cell Models
Objective We aimed to characterize the phenotypic spectrum and functional consequences associated with variants in HCN2, encoding for the hyperpolarization‐activated cyclic nucleotide (HCN) gated channel 2. Methods GeneMatcher facilitated the recruitment of 21 individuals with HCN2 variants from 15 unrelated families, carrying HCN2 variants.
Clara Houdayer+52 more
wiley +1 more source
Visual Features in Stereo‐Electroencephalography to Predict Surgical Outcome: A Multicenter Study
Objective Epilepsy surgery needs predictive features that are easily implemented in clinical practice. Previous studies are limited by small sample sizes, lack of external validation, and complex computational approaches. We aimed to identify and validate visually stereo‐electroencephalography (SEEG) features with the highest predictive value for ...
Chifaou Abdallah+20 more
wiley +1 more source
Clinical characteristics of headache related to epilepsy: experience from a tertiary epilepsy center. [PDF]
Zhang S, Lv Z, Li J, Zhou D.
europepmc +1 more source
Perceived triggers of primary headache disorders: A meta-analysis
A. Pellegrino+4 more
semanticscholar +1 more source
Synthesis of Literature: Neurodegeneration in Moderate‐Severe TBI. Objective Although moderate‐to‐severe traumatic brain injury (msTBI) was once considered a static neural event following resolution of acute injuries, numerous studies now demonstrate progressive losses to volume and white matter integrity in the months and years postinjury, leading to ...
Bhanu Sharma+4 more
wiley +1 more source
Relationships between headache and amine changes after administration of reserpine to migrainous patients. [PDF]
G. Curzon+2 more
openalex +1 more source
Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks
Objective The objective of this study was to evaluate the timing of change of Alzheimer's disease (AD) plasma biomarkers (Aβ42/Aβ40, p‐tau217, p‐tau181, GFAP, and NfL) from six different assay platforms, alongside established AD biomarkers, using amyloid and tau positron emission tomography (PET)‐based AD progression timelines.
Marta Milà‐Alomà+27 more
wiley +1 more source